EU Regulators Fine Johnson & Johnson, Novartis AG 16 Million Euros For Generic Drug Deal
Published: Dec 10, 2013
European Union antitrust regulators fined drugmakers Johnson & Johnson and Novartis a total of 16 million euros ($21.95 million) on Tuesday for blocking the sale of a generic painkiller in the Dutch market. The European Commission said in a statement that the deal between the two companies meant patients did not have access to the cheaper generic version of fentanyl for 17 months starting from July 2005. Johnson & Johnson and its Dutch unit, Janssen-Cilag, were fined 10.8 million euros while Novartis and its Dutch subsidiary, Sandoz, were fined 5.5 million euros.
Help employers find you! Check out all the jobs and post your resume.